Dietary induction of NQO1 increases the antitumour activity of mitomycin C in human colon tumours in vivo

被引:27
作者
Begleiter, A
Leith, MK
Thliveris, JA
Digby, T
机构
[1] Univ Manitoba, Dept Internal Med, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada
[2] Univ Manitoba, Dept Pharmacol & Therapeut, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada
[3] Univ Manitoba, Dept Human Anat & Cell Sci, Winnipeg, MB R3E 3J7, Canada
基金
加拿大健康研究院;
关键词
mitomycin C; antitumour activity; NQO1; diet; induction;
D O I
10.1038/sj.bjc.6602171
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The bioreductive antitumour agent, mitomycin C (MMC), requires activation by reductive enzymes like NAD(P)H:quinone oxidoreductase 1 (NQO1). We used a novel approach to increase MMC efficacy by selectively inducing NQO1 in tumour cells in vivo. CD-1 nude mice were implanted with HCT116 cells, and fed control diet or diet containing 0.3% of the NQO1 inducer, dimethyl fumarate (DMF). The mice were then treated with saline, 2.0, 3.5 or 2.0 mg kg(-1) MMC and dicoumarol, an NQO1 inhibitor. The DMF diet increased NQO1 activity by 2.5-fold in the tumours, but had no effect in marrow cells. Mice given control diet/2.0 mg kg(-1) MMC had tumours with the same volume as control mice; however, mice given DMF diet/2.0 mg kg(-1) MMC had significantly smaller tumours. Tumour volumes in mice given DMF/2.0 mg kg(-1) MMC were similar to those in mice given control diet/3.5 mg kg(-1) MMC. Tumour inhibition was partially reversed in mice given DMF/2.0 mg kg(-1) MMC and dicoumarol. DMF diet/2.0 mg kg(-1) MMC treatment did not increase myelosuppression and did not produce any organ toxicity. These results provide strong evidence that dietary inducers of NQO1 can increase the antitumour activity of bioreductive agents like MMC without increasing toxicity.
引用
收藏
页码:1624 / 1631
页数:8
相关论文
共 50 条
[1]  
BEALL HD, 1995, MOL PHARMACOL, V48, P499
[2]  
Begleiter A, 1996, BRIT J CANCER, V74, pS9
[3]   INCREASED SENSITIVITY OF QUINONE RESISTANT CELLS TO MITOMYCIN-C [J].
BEGLEITER, A ;
ROBOTHAM, E ;
LACEY, G ;
LEITH, MK .
CANCER LETTERS, 1989, 45 (03) :173-176
[4]  
BEGLEITER A, 1993, MOL PHARMACOL, V44, P210
[5]  
BEGLEITER A, 1992, MOL PHARMACOL, V41, P677
[6]   Clinical applications of quinone-containing alkylating agents [J].
Begleiter, A .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2000, 5 :E153-E171
[7]   NAD(P)H-QUINONE OXIDOREDUCTASE(1) (DT-DIAPHORASE) EXPRESSION IN NORMAL AND TUMOR-TISSUES [J].
BELINSKY, M ;
JAISWAL, AK .
CANCER AND METASTASIS REVIEWS, 1993, 12 (02) :103-117
[8]   EO9 - RELATIONSHIP BETWEEN DT-DIAPHORASE LEVELS AND RESPONSE IN-VITRO AND IN-VIVO [J].
COLLARD, J ;
MATTHEW, AM ;
DOUBLE, JA ;
BIBBY, MC .
BRITISH JOURNAL OF CANCER, 1995, 71 (06) :1199-1203
[9]   Induction of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and normal cells and effect on anti-tumour activity of bioreductive agents [J].
Doherty, GP ;
Leith, MK ;
Wang, X ;
Curphey, TJ ;
Begleiter, A .
BRITISH JOURNAL OF CANCER, 1998, 77 (08) :1241-1252
[10]   MITOMYCIN - 10 YEARS AFTER APPROVAL FOR MARKETING [J].
DOLL, DC ;
WEISS, RB ;
ISSELL, BF .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (02) :276-286